Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Cash from Financing Activities of -$10.9 million for Q1 2026, down 2355.99% year-over-year from $484000.0 in Q1 2025, and down 138.82% quarter-over-quarter from -$4.6 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 2355.99% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$10.8 million (down 24.95% YoY), while the FY2025 annual figure was $601000.0, up 105.16% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$10.9 million, down from -$4.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $19.1 million in Q1 2023, with the low at -$10.9 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is -$373000.0 (2023), against an average of $174000.0.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities jumped 1911.31% in 2022, then sank 2355.99% in 2026.
- Rigel Pharmaceuticals' Cash from Financing Activities stood at -$2.1 million in 2022, then surged by 123.19% to $486000.0 in 2023, then jumped by 201.44% to $1.5 million in 2024, then plunged by 412.08% to -$4.6 million in 2025, then sank by 138.82% to -$10.9 million in 2026.
- Business Quant data shows RIGL's Cash from Financing Activities at -$10.9 million in Q1 2026, -$4.6 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | -11.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | -10.92 Mn |
| Mar 31, 2026 | -10.92 Mn |
| Dec 31, 2025 | -4.57 Mn |
| Dec 31, 2025 | -4.57 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -9.84 Mn |
| Sep 30, 2024 | -9.84 Mn |
| Jun 30, 2024 | -752,000.00 |
| Jun 30, 2024 | -752,000.00 |
| Mar 31, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.51 Mn |